Fábio M. Iwamoto
About
Fábio M. Iwamoto is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Neurology.
According to data from OpenAlex, Fábio M. Iwamoto has authored 148 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 92 papers in Genetics, 44 papers in Pulmonary and Respiratory Medicine and 42 papers in Neurology. Recurrent topics in Fábio M. Iwamoto's work include Glioma Diagnosis and Treatment (90 papers), Brain Metastases and Treatment (35 papers) and CNS Lymphoma Diagnosis and Treatment (23 papers). Fábio M. Iwamoto is often cited by papers focused on Glioma Diagnosis and Treatment (90 papers), Brain Metastases and Treatment (35 papers) and CNS Lymphoma Diagnosis and Treatment (23 papers). Fábio M. Iwamoto collaborates with scholars based in United States, Brazil and Germany. Fábio M. Iwamoto's co-authors include Lauren E. Abrey, Lisa M. DeAngelis, Lakshmi Nayak, Howard A. Fine, Teri Kreisl, Andrew B. Lassman, Philip H. Gutin, Kathryn Beal, Joohee Sul and Katherine S. Panageas and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.
In The Last Decade
Fábio M. Iwamoto
142 papers receiving 4.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Fábio M. Iwamoto United States | 37 | 3.0k | 1.4k | 1.2k | 937 | 886 | 148 | 4.6k | ||
| Philippe Métellus France | 38 | 2.2k 0.7× | 1.3k 0.9× | 1.8k 1.4× | 765 0.8× | 770 0.9× | 170 | 5.3k | ||
| Yoshitaka Narita Japan | 37 | 2.6k 0.9× | 753 0.6× | 1.2k 1.0× | 2.0k 2.1× | 615 0.7× | 234 | 5.6k | ||
| Marica Eoli Italy | 30 | 2.0k 0.7× | 618 0.5× | 636 0.5× | 1.0k 1.1× | 574 0.6× | 152 | 3.8k | ||
| Mathilde C.M. Kouwenhoven Netherlands | 33 | 3.1k 1.0× | 623 0.5× | 1.3k 1.0× | 1.7k 1.9× | 516 0.6× | 99 | 5.2k | ||
| Enrico Franceschi Italy | 38 | 4.1k 1.4× | 809 0.6× | 2.0k 1.6× | 1.4k 1.5× | 342 0.4× | 193 | 5.8k | ||
| M. Kelly Nicholas United States | 26 | 2.8k 0.9× | 564 0.4× | 1.2k 1.0× | 1.6k 1.7× | 301 0.3× | 64 | 4.5k | ||
| Yukihiko Sonoda Japan | 32 | 2.2k 0.7× | 592 0.4× | 552 0.4× | 1.6k 1.8× | 309 0.3× | 224 | 4.6k | ||
| Regina I. Jakacki United States | 35 | 2.3k 0.8× | 1.8k 1.3× | 756 0.6× | 969 1.0× | 209 0.2× | 94 | 4.0k | ||
| Keishi Makino Japan | 27 | 1.4k 0.5× | 608 0.4× | 912 0.7× | 1.5k 1.6× | 331 0.4× | 95 | 4.2k | ||
| Melike Pekmezci United States | 28 | 1.4k 0.5× | 556 0.4× | 744 0.6× | 1.3k 1.4× | 237 0.3× | 101 | 4.0k |
Countries citing papers authored by Fábio M. Iwamoto
Since
Specialization
Citations
This map shows the geographic impact of Fábio M. Iwamoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fábio M. Iwamoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fábio M. Iwamoto more than expected).
Fields of papers citing papers by Fábio M. Iwamoto
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Fábio M. Iwamoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fábio M. Iwamoto. The network helps show where Fábio M. Iwamoto may publish in the future.
Co-authorship network of co-authors of Fábio M. Iwamoto
This figure shows the co-authorship network connecting the top 25 collaborators of Fábio M. Iwamoto. A scholar is included among the top collaborators of Fábio M. Iwamoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fábio M. Iwamoto. Fábio M. Iwamoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Omuro, Antonio, Lisa M. DeAngelis, Mei‐Yin C. Polley, et al.. (2025). Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma. Neuro-Oncology. 28(2). 371–382.
2.
Kinslow, Connor J., Soumyajit Roy, Fábio M. Iwamoto, et al.. (2024). The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas. Neuro-Oncology. 26(10). 1839–1849.
3.
Beck, J. Thaddeus, Dale R. Shepard, Olivier Dumas, et al.. (2024). A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799544 (ARRY-134) as a single agent and in combination with PF-07799933 BRAF dimer inhibitor, in participants 16 years and older with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS3180–TPS3180.
4.
Dumbrava, Ecaterina E., Fábio M. Iwamoto, Mark Agulnik, et al.. (2024). Abstract CT066: Phase 1 study of MDM2 antagonist ASTX295 in patients with solid tumors with wild-type TP53. Cancer Research. 84(7_Supplement). CT066–CT066.
5.
Merrell, Ryan, Patrick Y. Wen, Deborah Forst, et al.. (2024). Randomized phase IIb trial of a CMV vaccine immunotherapeutic candidate (VBI-1901) in recurrent glioblastomas.. Journal of Clinical Oncology. 42(16_suppl). TPS2100–TPS2100.
6.
Sloan, Andrew E., Kathryn Winter, Mark R. Gilbert, et al.. (2024). NRG-BN002: Phase I study of ipilimumab, nivolumab, and the combination in patients with newly diagnosed glioblastoma. Neuro-Oncology. 26(9). 1628–1637.
7.
Piha‐Paul, Sarina A., Macarena I. de la Fuente, Fábio M. Iwamoto, et al.. (2024). Interim analysis of ABM-1310, a blood-brain barrier-penetrant BRAF inhibitor, in patients with BRAF V600-mutated solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 3107–3107.
8.
Iwamoto, Fábio M., Neel I. Nissen, David A. Reardon, et al.. (2023). CTIM-27. PERIPHERAL BIOMARKER ANALYSIS OF T CELL-MEDIATED COLLAGEN REMODELING CORRELATES WITH TUMOR RESPONSES IN A PHASE IIA TRIAL OF VACCINE IMMUNOTHERAPEUTIC CANDIDATE (VBI-1901). Neuro-Oncology. 25(Supplement_5). v68–v68.
9.
Kinslow, Connor J., Ali I. Rae, Kekoa Taparra, et al.. (2023). MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas. Clinical Cancer Research. 29(21). 4399–4407.
10.
Iwamoto, Fábio M., Vinai Gondi, Nicholas Butowski, et al.. (2022). CTNI-49. EARLY SIGNAL OF ACTIVITY FROM A PHASE 2 STUDY OF ST101, A FIRST-IN-CLASS PEPTIDE ANTAGONIST OF CCAAT/ENHANCER-BINDING PROTEIN Β (C/EBPΒ), IN RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology. 24(Supplement_7). vii83–vii83.
11.
Kim, Ju‐Young, Jennifer Bordeaux, Thai H. Tran, et al.. (2020). Predictive evaluation of quantitative spatial profiling of the tumor microenvironment by multiplex immunofluorescence in recurrent glioblastoma treated with PD-1 inhibitors.. Journal of Clinical Oncology. 38(15_suppl). e14524–e14524.
12.
Lukas, Rimas V., Derek A. Wainwright, Craig Horbinski, Fábio M. Iwamoto, & Adam M. Sonabend. (2019). Immunotherapy Against Gliomas: is the Breakthrough Near?. Drugs. 79(17). 1839–1848.
13.
Peereboom, David M., Burt Nabors, Priya Kumthekar, et al.. (2018). Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival.. Journal of Clinical Oncology. 36(15_suppl). 2058–2058.
14.
Weller, Michael, Nicholas Butowski, David Tran, et al.. (2016). ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA. Neuro-Oncology. 18(suppl_6). vi17–vi18.
15.
Ho, Jennifer, John Ondos, Holly Ning, et al.. (2013). Chemoirradiation for Glioblastoma Multiforme: The National Cancer Institute Experience. PLoS ONE. 8(8). e70745–e70745.
16.
Iwamoto, Fábio M., Kathleen R. Lamborn, John G. Kuhn, et al.. (2011). A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro-Oncology. 13(5). 509–516.
17.
Wind, Joshua J., et al.. (2011). Immediate Titanium Mesh Cranioplasty for Treatment of Postcraniotomy Infections. World Neurosurgery. 79(1). 207.e11–207.e13.
18.
Fraum, Tyler J., Svetlana Pack, Russell R. Lonser, et al.. (2011). Spinal cord glioneuronal tumor with neuropil-like islands with 1p/19q deletion in an adult with low-grade cerebral oligodendroglioma. Journal of Neuro-Oncology. 107(2). 421–426.
19.
Clarke, Jennifer, Fábio M. Iwamoto, Joohee Sul, et al.. (2009). Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma. Journal of Clinical Oncology. 27(23). 3861–3867.
20.
Shapiro, Lauren, Sasan Karimi, Philip H. Gutin, et al.. (2009). Patterns of Failure Following Concurrent Bevacizumab and Hypofractionated Stereotactic Radiotherapy for Recurrent High-grade Glioma. International Journal of Radiation Oncology*Biology*Physics. 75(3). S125–S125.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Philippe Métellus Breakdown of academic impact, for papers by Yoshitaka Narita Breakdown of academic impact, for papers by Marica Eoli Breakdown of academic impact, for papers by Mathilde C.M. Kouwenhoven Breakdown of academic impact, for papers by Enrico Franceschi Breakdown of academic impact, for papers by M. Kelly Nicholas Breakdown of academic impact, for papers by Yukihiko Sonoda Breakdown of academic impact, for papers by Regina I. Jakacki Breakdown of academic impact, for papers by Keishi Makino Breakdown of academic impact, for papers by Melike Pekmezci